WHO-GMP Certified Commercial Pack · Product Code: AKP-176
Glimepiride 1 mg, Metformin HCl 500 mg (SR) & Voglibose 0.2 mg Tablets
Formulation Overview: Triple glycemic regimen combining glimepiride 1 mg, sustained-release metformin HCl 500 mg, and alpha-glucosidase inhibitor voglibose 0.2 mg to blunt post-meal carbohydrate absorption spikes. Formulated with Glimepiride 1 mg + Metformin HCl 500 mg (SR) + Voglibose 0.2 mg (1 mg + 500 mg (SR) + 0.2 mg) in Sustained-Release Triple Tablets dosage form under Anti-Diabetic Medication, manufactured to IP / BP / USP Compendial standards and supplied in 10 x 10 Alu-Alu / Blister Pack with complete eCTD/ACTD regulatory dossiers, Zone IVb stability, and batch CoA for African NRAs (NAFDAC, PPB, SAHPRA, TMDA, FDA Ghana) and global tenders.
| Item Code (SKU) | AKP-176 |
|---|---|
| Catalog Reference | AKP-176 · SN 176 |
| Therapeutic Sector | Anti-Diabetic Medication |
| Dosage Form | Sustained-Release Triple Tablets |
| Active Ingredient | Glimepiride 1 mg + Metformin HCl 500 mg (SR) + Voglibose 0.2 mg |
| Strength / Purity | 1 mg + 500 mg (SR) + 0.2 mg |
| Clinical Indication | Type 2 diabetes mellitus with pronounced postprandial glucose excursions |
| Specification Standard | IP / BP / USP Compendial |
| Packaging Format | 10 x 10 Alu-Alu / Blister Pack |
| Shelf Life | 24–36 Months |
| Storage Conditions | Store below 25°C in a dry place, protect from light and moisture |
| Minimum Order Quantity | 1000 Packs |
| Regulatory / Analytical Docs | Full eCTD / ACTD Modules 1–5 + Zone IVb Stability Available |
| African & Global NRA Readiness | NAFDAC (Nigeria), PPB (Kenya), SAHPRA (SA), TMDA (Tanzania), FDA Ghana, AIRP, ARP, EFDA |
| Stock Availability | In Stock · Immediate Commercial Dispatch |
| Supply Status | Commercial Export Ready |